Predict your next investment

HEALTHCARE | Drug Development
aardenpharma.com

See what CB Insights has to offer

Executives

4

Board of Directors

2

Aarden Pharmaceuticals Board of Directors

2 Board of directors

Aarden Pharmaceuticals has 2 board of directors, including Christopher LeMasters.

Name

Firm

Work History

Other Seats

Christopher LeMasters

Chris LeMasters is the EVP & Chief Operating Officer of Amplyx Pharmaceuticals, now a wholly owned subsidiary of Pfizer, Inc. Amplyx has focused on the development of novel first-in-class therapies for infectious disease affecting immune compromised patients. He led the strategic efforts that resulted in Amplyx’s acquisition by Pfizer in April 2021. Mr. LeMasters was previously Executive Vice President and Chief Business Officer of Mirati Therapeutics, a clinical-stage oncology company, where he was responsible for corporate development, strategy and investor relations. During his three years in this role, he oversaw the successful expansion of the company and its market capitalization from $100 million in 2016 to nearly $5 billion in December 2019. Prior to joining Mirati, Mr. LeMasters served as the CEO of Promosome, a privately held mRNA re-engineering and biotherapeutics company co-founded by Nobel Laureate Dr. Gerald M. Edelman of The Scripps Research Institute in La Jolla, California. Previously, Mr. LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company. Mr. LeMasters also served as co-founder and chief business officer of Cabrellis Pharmaceuticals, Inc., where he negotiated its acquisition by Pharmion Corporation for $104 million, and as vice president, corporate development of Conforma Therapeutics, where he negotiated its acquisition by Biogen IDEC for $250 million. Mr. LeMasters also worked in the corporate business development group at Eli Lilly & Company and was responsible for the successful negotiation of numerous partnerships and licenses across a range of therapeutic areas. Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning. Mr. LeMasters currently serves as a board member of the Hoosier Cancer Research Network, a clinical research organization.

Aarden Pharmaceuticals

Ken Green

Aarden Pharmaceuticals

Name

Christopher LeMasters

Ken Green

Firm

Work History

Chris LeMasters is the EVP & Chief Operating Officer of Amplyx Pharmaceuticals, now a wholly owned subsidiary of Pfizer, Inc. Amplyx has focused on the development of novel first-in-class therapies for infectious disease affecting immune compromised patients. He led the strategic efforts that resulted in Amplyx’s acquisition by Pfizer in April 2021. Mr. LeMasters was previously Executive Vice President and Chief Business Officer of Mirati Therapeutics, a clinical-stage oncology company, where he was responsible for corporate development, strategy and investor relations. During his three years in this role, he oversaw the successful expansion of the company and its market capitalization from $100 million in 2016 to nearly $5 billion in December 2019. Prior to joining Mirati, Mr. LeMasters served as the CEO of Promosome, a privately held mRNA re-engineering and biotherapeutics company co-founded by Nobel Laureate Dr. Gerald M. Edelman of The Scripps Research Institute in La Jolla, California. Previously, Mr. LeMasters held senior management positions at several biotherapeutics companies, most recently as co-founder and chief business officer of Tragara Pharmaceuticals, a clinical-stage cancer therapeutics company. Mr. LeMasters also served as co-founder and chief business officer of Cabrellis Pharmaceuticals, Inc., where he negotiated its acquisition by Pharmion Corporation for $104 million, and as vice president, corporate development of Conforma Therapeutics, where he negotiated its acquisition by Biogen IDEC for $250 million. Mr. LeMasters also worked in the corporate business development group at Eli Lilly & Company and was responsible for the successful negotiation of numerous partnerships and licenses across a range of therapeutic areas. Earlier in his career, he was a management consultant with Coopers & Lybrand Consulting and an operational auditor with Owens Corning. Mr. LeMasters currently serves as a board member of the Hoosier Cancer Research Network, a clinical research organization.

Other Seats

Aarden Pharmaceuticals

Aarden Pharmaceuticals

Aarden Pharmaceuticals Management Team

4 Team Members

Aarden Pharmaceuticals has 4 executives. Aarden Pharmaceuticals's founder is Christopher C LeMasters. Aarden Pharmaceuticals's current Chief Executive Officer, President is Gary M Noonan.

Name

Work History

Title

Status

Christopher C LeMasters

Founder

Current

Zhongyin Zhang

Founder

Current

Gary M Noonan

Chief Executive Officer, President

Current

Francis J. Burrows

Chief Security Officer

Former

Name

Christopher C LeMasters

Zhongyin Zhang

Gary M Noonan

Francis J. Burrows

Work History

Title

Founder

Founder

Chief Executive Officer, President

Chief Security Officer

Status

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.